X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs WOCKHARDT - Comparison Results

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA WOCKHARDT AJANTA PHARMA/
WOCKHARDT
 
P/E (TTM) x 21.0 -19.0 - View Chart
P/BV x 4.0 1.3 299.1% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 AJANTA PHARMA   WOCKHARDT
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
WOCKHARDT
Mar-18
AJANTA PHARMA/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs1,8181,012 179.6%   
Low Rs1,106532 208.1%   
Sales per share (Unadj.) Rs239.5355.9 67.3%  
Earnings per share (Unadj.) Rs52.8-60.3 -87.6%  
Cash flow per share (Unadj.) Rs59.5-46.8 -127.3%  
Dividends per share (Unadj.) Rs00.01 0.0%  
Dividend yield (eoy) %00 0.0%  
Book value per share (Unadj.) Rs230.0257.8 89.2%  
Shares outstanding (eoy) m88.77110.63 80.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.12.2 281.5%   
Avg P/E ratio x27.7-12.8 -216.3%  
P/CF ratio (eoy) x24.6-16.5 -148.9%  
Price / Book Value ratio x6.43.0 212.4%  
Dividend payout %00 0.0%   
Avg Mkt Cap Rs m129,78285,379 152.0%   
No. of employees `0006.86.3 108.7%   
Total wages/salary Rs m3,7659,371 40.2%   
Avg. sales/employee Rs Th3,128.46,295.0 49.7%   
Avg. wages/employee Rs Th554.01,498.3 37.0%   
Avg. net profit/employee Rs Th689.7-1,066.3 -64.7%   
INCOME DATA
Net Sales Rs m21,25839,369 54.0%  
Other income Rs m2421,202 20.1%   
Total revenues Rs m21,49940,571 53.0%   
Gross profit Rs m6,58418 35,977.6%  
Depreciation Rs m5961,495 39.9%   
Interest Rs m42,555 0.2%   
Profit before tax Rs m6,226-2,830 -220.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m1,539257 598.9%   
Profit after tax Rs m4,686-6,669 -70.3%  
Gross profit margin %31.00 66,630.4%  
Effective tax rate %24.7-9.1 -272.2%   
Net profit margin %22.0-16.9 -130.2%  
BALANCE SHEET DATA
Current assets Rs m12,23633,796 36.2%   
Current liabilities Rs m3,46126,917 12.9%   
Net working cap to sales %41.317.5 236.3%  
Current ratio x3.51.3 281.6%  
Inventory Days Days6079 75.9%  
Debtors Days Days8489 94.7%  
Net fixed assets Rs m11,14039,664 28.1%   
Share capital Rs m177553 32.0%   
"Free" reserves Rs m20,23727,968 72.4%   
Net worth Rs m20,41428,522 71.6%   
Long term debt Rs m1021,731 0.0%   
Total assets Rs m24,48681,620 30.0%  
Interest coverage x1,519.4-0.1 -1,413,160.7%   
Debt to equity ratio x00.8 0.1%  
Sales to assets ratio x0.90.5 180.0%   
Return on assets %19.2-5.0 -380.1%  
Return on equity %23.0-23.4 -98.2%  
Return on capital %30.5-7.7 -397.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m11,6679,807 119.0%   
Fx outflow Rs m1,6161,789 90.3%   
Net fx Rs m10,0528,019 125.4%   
CASH FLOW
From Operations Rs m2,854684 417.0%  
From Investments Rs m-2,6046,302 -41.3%  
From Financial Activity Rs m-2-7,695 0.0%  
Net Cashflow Rs m248-664 -37.4%  

Share Holding

Indian Promoters % 73.8 74.5 99.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 2.3 67.4%  
FIIs % 7.6 7.7 98.7%  
ADR/GDR % 0.0 0.1 -  
Free float % 17.0 15.4 110.4%  
Shareholders   20,968 67,757 30.9%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   AUROBINDO PHARMA  ORCHID PHARMA LTD  SANOFI INDIA  J.B.CHEMICALS  MERCK  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 66 Points Higher; Realty and Consumer Durable Stocks Witness Buying(Closing)

Indian share markets continued to witness volatility during closing hours and ended their day on a flat note.

Related Views on News

PIRAMAL ENTERPRISES Plunges by 5%; BSE HEALTHCARE Index Down 1.1% (Market Updates)

Jun 19, 2019 | Updated on Jun 19, 2019

PIRAMAL ENTERPRISES share price has plunged by 5% and its current market price is Rs 1,899. The BSE HEALTHCARE is down by 1.1%. The top gainers in the BSE HEALTHCARE Index are CAPLIN POINT (up 3.5%) and GRANULES INDIA (up 3.0%). The top losers are PIRAMAL ENTERPRISES (down 5.2%) and WOCKHARDT (down 7.0%).

WOCKHARDT Plunges by 5%; BSE HEALTHCARE Index Down 0.2% (Market Updates)

Jun 19, 2019 | Updated on Jun 19, 2019

WOCKHARDT share price has plunged by 5% and its current market price is Rs 378. The BSE HEALTHCARE is down by 0.2%. The top gainers in the BSE HEALTHCARE Index are GRANULES INDIA (up 6.3%) and APOLLO HOSPITALS (up 2.0%). The top losers is WOCKHARDT (down 5.1%).

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

Just One Stock Made Buffett Billions - And Can Make You Crores(Profit Hunter)

Jun 6, 2019

Coca Cola is arguably one of Warren Buffet's best stock picks. But did you know that small investors picked up the stock five decades before Buffet? Read on...

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why Modi 2.0 Will Be Great for These 7 Stocks(Profit Hunter)

Jun 10, 2019

The government's focus on Infra, electricity, water for all will be the key factors for Sensex 1,00,000.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jun 19, 2019 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS